Qiming Venture Partners is a prominent venture capital firm based in Shanghai, China, founded in 2006. With additional offices in Beijing, Suzhou, Hong Kong, and Singapore, the firm focuses on early to growth-stage investments across various sectors, including healthcare, information technology, consumer goods, mobile internet, artificial intelligence, and clean technology. Qiming Venture Partners has a strong track record, having invested in over 530 innovative companies, with more than 200 achieving successful exits through public offerings or mergers and acquisitions. The firm is recognized for its deep technical expertise and hands-on operational support, making it a preferred partner for CEOs and startups seeking to scale their operations. Its partners are often sought after as board members, reflecting their status as respected business leaders and thought leaders in the venture capital landscape.
Room3906 Jinmao Tower, 88 Century Boulevard, Shanghai 200121, China
Zhang Ao
Executive Director
Cyrus Chan
Associate
Nan Chen
Principal
David Chu
Partner
Anna French
Managing Partner
Yuxin Fu
Vice President
Jinda Gao
Principal
Kuantai Yeh
Partner
Robert Headley
Partner
Maykin Ho
Venture Partner
William Hu
Managing Partner
Duane Kuang
Founding Managing Partner
Nisa Leung
Managing Partner
Dingzheng Li
Vice President
Jing Liu
Vice President
Chang Liu
Associate
Bin Liu
Vice President
Biao Lu
Associate
Shuo Mao
Principal
Gary Rieschel
Founder and Managing Partner
Motao Sun
Vice President
Amy Tang
Venture Partner
Yi Tang
Principal
Shiyu Wang
Partner
Bonnie Wang
Principal
Rachel Wang
Venture Partner
James Wang
Venture Partner
Jing Wu
Partner
Gillian Xu
RMB funds CFO
Peter (Ming) Yin
Principal, Cleantech
Janet Yu
Partner
Yafeng Zhou
Associate
Alex Zhou
Partner
Zhiyuan Zhou
Associate
Jing-Shan Hu Ph.D
Venture Partner of Healthcare
Past deals in Shanghai
FXiaoKe
Venture Round in 2024
FXiaoKe designs a cloud-based sales management platform that provides management tools for Chinese companies. Its platform provides services related to field operation management, distribution chain management and customer relationship management, enabling small and medium-sized enterprises to manage their sales through a social interaction platform that combines features of dynamic CRM and enterprise WeChat. FXiaoKe develops enterprise software solutions. It offers online office automation services including sharing information between personal computers and smart phones. It also provides customer management services. Luo Xu founded FXiaoKe in December 2011, with its headquarters in Beijing, China.
Alpha Biopharma
Series B in 2024
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
DK Medtech
Series E in 2024
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Yanshengchao
Angel Round in 2024
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Leapstack
Series C in 2023
Leapstack is an insurance technology company based in Shanghai, with additional offices in Beijing and Nanjing. Founded in February 2016, it focuses on developing big data artificial intelligence solutions tailored for commercial insurance companies and social security management agencies. The company's platform enhances the insurance claims process by offering services such as risk control monitoring, post-medical reimbursement, anti-fraud measures, and compliance identification. By addressing inefficiencies in the industry, Leapstack aims to improve operational effectiveness and provide comprehensive data analysis and management tools for its clients.
Yanshengchao
Angel Round in 2023
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Puanita
Series A in 2023
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Cornerstone Robotics
Series B in 2023
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Ailomics Therapeutics
Angel Round in 2023
Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.
CuroVax
Series B in 2023
CuroVax researches and focuses on developing and producing vaccines for various diseases. It provides biotechnology and microbiology services to improve the health and medical industry. CuroVax was founded in 2011 and is based in Changzhou City, China.
DK Medtech
Venture Round in 2023
DK Medtech, founded in 2015 and headquartered in Suzhou, China, specializes in the development and production of balloon catheter medical devices. The company is recognized as a leader in the medical device industry, focusing on innovative technologies that aim to meet the evolving challenges in healthcare. Through its commitment to excellence, DK Medtech strives to create impactful solutions that enhance patient care and improve medical outcomes.
Zeen Health
Series A in 2023
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.
1 Yong Cloud
Series B in 2023
1 Yong Cloud is a Beijing-based company founded in 2017 that specializes in developing a tumor diagnosis and treatment standardization platform. This platform is designed to assist physicians in creating personalized diagnosis and treatment plans for patients with tumor diseases. By collecting and translating medical data, 1 Yong Cloud aims to enhance the quality and consistency of medical care while rationalizing treatment expenses. The company's comprehensive data and system services support healthcare professionals in improving the overall effectiveness of tumor diagnosis and treatment.
moodytiger
Convertible Note in 2023
moodytiger is a technical athletic apparel brand for children from age of 4 to 16. Today, kids from more than 100 countries, from United States to Australia, from Singapore to Hong Kong, have worn moodytiger outfits in their wonderful active adventure! Born to redefine kids’ athlectic wear from day one, our products are specially tailored for children with perfect combination of high-tech fabrics and fashion-forward designs, and functionally suited for multiple sports, including tennis, skiing, skating, swimming, outdoor, and everyday active living. As one of the fastest growing and most innovative brands in the category, we thrive to be the new industry benchmark setter with what we do.
Ricoton
Series A in 2023
Ricoton specializes in the development and production of medical devices aimed at treating or preventing cerebrovascular diseases. Founded in 2011 and based in Hunan, China, the company manufactures an array of intervention devices, including microcatheters, guidewires, and various tools for ischemic stroke treatment. Their product offerings feature a comprehensive three-piece set that includes a micro guide wire, micro catheter, and support catheter for vascular access, as well as a thrombectomy stent and balloon guide catheter. Ricoton's innovative solutions provide a one-stop thrombectomy option for patients, enhancing the effectiveness of cerebrovascular interventions.
Allorion Therapeutics
Series B in 2023
Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operational facilities in Natick, Massachusetts, and Guangzhou, China, Allorion specializes in developing mutant selective and isoform-specific drugs through unconventional methods targeting established disease pathways. This approach aims to enhance the efficacy of treatments and reduce the likelihood of resistance in patients, contributing to improved therapeutic outcomes.
SinoUnited Health
Series C in 2023
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
Biotree Technology
Series A in 2023
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Tlibrium
Angel Round in 2022
Tlibrium provides expertise in the technology promotion and application service industry. Tlibrium was founded in 2022 and was headquartered in Shanghai, China.
PureVision
Series A in 2022
PureVision focuses on developing medical devices for ophthalmology. PureVision was founded in 2022 and was headquartered in Wenzhou, Zhejiang China.
PlusLife Biotech
Series A in 2022
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
Bitworx
Series A in 2022
Bitworx is a company based in Chengdu, China, specializing in product development and applications that leverage advanced algorithm and chip technology for communication, sensing, and detection. Currently, Bitworx is operating in stealth mode, which indicates that it is in the early stages of its business activities and may not yet be publicly disclosing its specific projects or technologies. The focus on communication and sensing technologies suggests a commitment to innovation in fields that require precise detection and data transmission capabilities.
Intellinosis
Angel Round in 2022
Intellinosis is a diagnostic company that focuses on developing molecular diagnostic reagents. Intellinosis is headquartered in Minhang District, China.
XellSmart
Series A in 2022
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
Focallure
Series B in 2022
Focallure is a cosmetic company that focuses on producing beauty products. Focallure is headquartered in Guangzhou, China.
Prismlab China
Series C in 2022
Prismlab China Ltd. is a high-tech enterprise established in 2005, specializing in the development, production, and sales of high-speed light-curing 3D printers. The company integrates optical, mechanical, electrical technology, and computer software and hardware, along with photopolymer materials, to produce advanced rapid prototyping machines based on SLA technology. With a global presence, its products are distributed across over 50 countries and regions, earning recognition and acclaim from users worldwide for their performance and innovation.
Ailomics Therapeutics
Seed Round in 2022
Ailomics Therapeutics, founded in 2022 and headquartered in Shanghai, China, is dedicated to developing innovative drugs for the treatment of immune diseases and tumors. The company utilizes a computational biology platform to analyze multi-omics data from patients, which aids in discovering novel drug mechanisms and targets that contribute to disease progression. Through this approach, Ailomics aims to enhance the understanding of complex diseases and advance the development of effective therapeutic solutions.
OriginCell
Series B in 2022
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Norm Medtech
Series B in 2022
Norm Medtech focuses on developing interventional medical devices. Norm Medtech is headquartered in Zhejiang, China.
Biotree Technology
Series A in 2022
Biotree is a high-tech enterprise focused on the application and development of advanced research technology in the life sciences sector. It specializes in metabolomics, offering early detection and analysis services in China. The company boasts a core team with significant expertise in metabolomics, encompassing scientific research services, health testing, and industrial testing. Biotree emphasizes mass spectrometry and metabolic testing, continually innovating in metabolomics products and technologies. It holds several patents in this field and is recognized for its accomplishments in metabolomics detection and analysis. Over the years, Biotree has demonstrated consistent growth and has maintained profitability for six consecutive years, solidifying its position in the biotechnological testing and consulting services market.
Resunbio
Series A in 2022
Resunbio provides micro-nano processing research and development precipitation. Resunbio is headquartered in Longhua, China.
Puanita
Angel Round in 2022
Puanita is a pet medicine brand seeking development with science and technology for pets. Puanita is headquartered in China.
Wayon
Funding Round in 2022
WayOn is a company based in Shanghai, China, specializing in electronic circuit protection and power semiconductor solutions for various industrial sectors. Established in 1996, WayOn offers an extensive range of products designed to ensure safety and reliability in electronic applications. Their offerings include PPTC, CPTC, and chip fuses for over-current protection, as well as TVS, thyristors, and ESD components for over-voltage protection. Additionally, the company provides thermal fuses for over-temperature protection and various power management components such as BMS, MOSFETs, and protection ICs. WayOn's products cater to diverse applications, including telecommunications, rechargeable batteries, IT equipment, automotive electronics, industrial machinery, and consumer electronics.
Yanshengchao
Seed Round in 2022
Room A204-1, Floor 2, Building 2, Yard 9, Yike Road Life Science Park, Changping District Beijing China
Medilink Therapeutics
Series B in 2022
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
WOWJOY TECHNOLOGY
Series A in 2022
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
Xiaoniao Kuaiyan
Series A in 2022
Xiaoniao Kuaiyan, headquartered in Beijing, China, offers home physical examination services that include regular health check-ups, tumor screenings, infection tests, chronic disease surveillance, and customized testing options for clients. In addition to these health services, the company also facilitates business cooperation between enterprises and provides customer service and professional training. Xiaoniao Kuaiyan is involved in formulating management procedures for quality inspection work and develops a product knowledge base to enhance its service offerings.
EigenCOMM
Series C in 2022
EigenCOMM Ltd. is a Shanghai-based company established in 2017, specializing in the research, development, and sales of cellular network internet chips. The firm focuses on providing complete solutions for Internet of Things (IoT) ecosystems, particularly in the realm of smart home appliances. EigenCOMM's product line includes standard NB-IoT terminal chips, which ensure comprehensive coverage of cellular data connections and extended standby times, positioning the company as a key player in the IoT market.
Tungee
Series B in 2021
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
SUPERHEXA
Series A in 2021
Superhexa is a cutting-edge hardware firm that specializes in personal consumer electronics. Superhexa was founded at October 15, 2020 by Xia Yongfeng and is located in Beijing.
Clinflash Heathcare Technology
Venture Round in 2021
Clinflash is a leading provider of cloud-based solution and relevant professional service in filed of clinical development in China. Clinflash aims to help pharmaceutical companies improve R&D effectiveness and efficiency through providing first class IT solution and professional service.
Sinogen Biopharma
Venture Round in 2021
Sinogen Biopharma is founded with a vision to bridge China's biotech innovation to the US pharma market. The company licenses and develops innovative drugs from China.
Xinchuangyuan Semiconductor
Series A in 2021
Xinchuangyuan Semiconductor is a manufacturing company of electronic equipment. Xinchuangyuan Semiconductor was founded in 2021 and was headquartered in Wuhan, China.
Cornerstone Robotics
Series B in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Genlight
Series B in 2021
Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
Zeen Health
Venture Round in 2021
Zeen Health is a digital therapeutics company that specializes in providing personalized mental health services through a mobile application. Founded in 2019 and headquartered in Shenzhen, China, the company utilizes artificial intelligence technology to deliver evidence-based mental health solutions. By focusing on the individual needs of users, Zeen Health aims to improve mental wellness through innovative digital approaches.
Genevide
Angel Round in 2021
Genevide is a biotech company that specializes in gene research and development. Genevide was founded in 2019 and is located in Suzhou, Jiangsu, China.
XellSmart
Seed Round in 2021
XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.
WOWJOY TECHNOLOGY
Series A in 2021
WOWJOY TECHNOLOGY, based in Hangzhou, China, specializes in data-driven medical services through an internet-based platform. The company offers a range of informational technology solutions tailored for large hospital groups and their patients. Its services include integrated workstations for medical, imaging, laboratory, and pharmacy functions. By streamlining information processing procedures, WOWJOY TECHNOLOGY aims to enhance the efficiency of diagnosis, treatment, and billing in the healthcare sector.
PlusLife Biotech
Series A in 2021
PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.
moodytiger
Series B in 2021
moodytiger is a technical athletic apparel brand for children from age of 4 to 16. Today, kids from more than 100 countries, from United States to Australia, from Singapore to Hong Kong, have worn moodytiger outfits in their wonderful active adventure! Born to redefine kids’ athlectic wear from day one, our products are specially tailored for children with perfect combination of high-tech fabrics and fashion-forward designs, and functionally suited for multiple sports, including tennis, skiing, skating, swimming, outdoor, and everyday active living. As one of the fastest growing and most innovative brands in the category, we thrive to be the new industry benchmark setter with what we do.
Berry Oncology
Series B in 2021
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
Neuro3 Therapeutics
Seed Round in 2021
Neuro3 Therapeutics is a Hong Kong based company that advances medicines for CNS diseases.
SUPERHEXA
Seed Round in 2021
Superhexa is a cutting-edge hardware firm that specializes in personal consumer electronics. Superhexa was founded at October 15, 2020 by Xia Yongfeng and is located in Beijing.
Insight Lifetech
Series D in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
WeRide
Series C in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Hesai Technology
Series D in 2021
Hesai Technology, founded in 2014 and headquartered in Shanghai, China, specializes in the development, manufacture, and sale of three-dimensional light detection and ranging solutions, commonly known as LiDAR. The company focuses on designing advanced laser radar systems that support a variety of applications, primarily in autonomous and semi-autonomous vehicles equipped with advanced driver assistance systems. Additionally, Hesai's technology is utilized in other sectors, such as robotics for last-mile delivery and industrial processes, as well as in natural gas leak detection systems. The organization has structured its operations into two main segments: LiDAR and gas detection, with the LiDAR segment generating the majority of its revenue.
Insight Lifetech
Secondary Market in 2021
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Data Transmission Group
Secondary Market in 2021
Data Transmission Group is an Internet technology group focusing on big data services in the press and publishing industry. Data Transmission Group is committed to the digital transformation and upgrading of big data services in the press and publication industry and the digital transformation and upgrading of the media industry, creating a digital content profit model with content providers as the main commercial value, changing the way users acquire and disseminate knowledge, and leading the Internet + upgrade of China's news and publications Replacement and industrial development direction. At present, the group has nearly 200 employees, most of whom are senior publishing, Internet, and software R&D personnel. They have a complete independent R&D system and have rich research results in mobile Internet technology, storage technology, data mining, and publishing integration.
Render
Series A in 2021
Render is a Chinese manufacturer of high-tech medical products and solutions. Render is a Shenzhen-based company that was founded in 2010.
P&R Measurement Technology
Series C in 2021
P&R Measurement Technology Co., Ltd., founded in 2011 and headquartered in Zhuhai, China, specializes in the research, development, and supply of testing and automation solutions. The company caters to various industries, including motors, household appliances, consumer electronics, and energy power. With a strong emphasis on engineering signal processing and acoustic/vibration testing, P&R Measurement offers a range of custom and semi-custom engineering testing equipment, as well as data processing and finite element simulation analysis services. The company operates subsidiaries in Guangzhou, Suzhou, Hong Kong, and the United States, with additional offices in Qingdao, Hefei, Shunde, and Ningde, enhancing its capacity to serve a diverse clientele.
SinoUnited Health
Series C in 2021
SinoUnited Health is located in the heart of your community. This is for your convenience and means that they remain integrated in the city’s residential life. Throughout the clinic,thoughtful design and ease of use meet international standards, and provide excellent service experiences and comfort for every patient. SinoUnited Health was founded in 2004,with the goal of providing specialized rehabilitation and integrated pain management,sports medicine and orthopedics for Shanghai residents and visitors. Since that time,SinoUnited Health has developed a reputation for world-class medical services. They are committed to provide quality personal services,which deliver high customer satisfaction,and the outcomes that patients need. They focus on reliable diagnosis and proven treatment success which continue their reputation for excellence in the communities that they serve.
CastBox
Series C in 2021
CastBox is a spoken audio platform founded in 2016 and based in Beijing, China, with additional offices in Hong Kong and San Francisco. The platform allows users to easily find, access, and enjoy a wide range of spoken audio content, including podcasts, on-demand radio, and audiobooks, across multiple devices such as mobile phones, desktops, and smart home devices. CastBox employs proprietary technology, including curated podcast recommendations and an in-audio deep search feature powered by natural language processing and machine learning. This technology enables the platform to deliver personalized listening experiences tailored to individual user preferences and habits. The service is available in multiple languages, making it accessible to a global audience.
ZSHK Laboratories
Series A in 2021
ZSHK Lab is a company located in Wan Chai, Hong Kong Island, Hong Kong.
Sincere Edu
Series A in 2021
Sincere Edu Inc. is an online education company based in Beijing, China, founded in 2016. It specializes in providing educational services focused on accounting and finance, including training materials for the CPA exam and subjects such as tax laws, economic principles, financial management, and auditing. The company aims to create a comprehensive learning platform that supports financial professionals throughout their careers by addressing their diverse educational needs. Sincere Edu emphasizes the importance of knowledge sharing and has developed a teacher training system to enhance the quality of its educational offerings, ultimately helping clients improve their professional skills and learning efficiency in the financial industry.
Unisound
Series D in 2021
Beijing Yunzhisheng Information Technology Co., Ltd. specializes in intelligent voice and speech processing technologies. Founded in June 2012, the company has developed proprietary speech recognition technologies and offers middleware and cloud platforms that deliver professional speech recognition services to internet enterprises and users. Its core technology encompasses voice technology, language technology, knowledge computing, and big data analysis, facilitating efficient communication between customers and machines. The company's technology team is highly qualified, with over 80% of its members holding doctoral degrees and possessing more than a decade of experience in voice recognition research and development. By leveraging cloud computing and mobile internet technologies, Yunzhisheng aims to enhance user interaction with devices, minimizing the need for manual input.
Alpha Biopharma
Series B in 2021
Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor aimed at treating patients with epidermal growth factor receptor (EGFR) mutation positive non-small cell lung cancer (NSCLC) who have central nervous system (CNS) metastases. To enhance its research and development capabilities, Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consultancy and management team. The company emphasizes a comprehensive strategy that includes research and development, market engagement, and intellectual property protection. Additionally, it partners with leading contract research organizations (CROs), contract manufacturing organizations (CMOs), hospitals, and institutes to ensure the effective implementation of its programs through meticulous project management.
Fucunbao
Series C in 2021
Fucunbao is an application that provides medical management solutions specifically designed for rural communities in China. It operates an online insurance and medical portal that enables users to pay for insurance online, create reimbursement plans, and identify disease types. The platform aims to enhance access to insurance and medical services for underserved populations. By leveraging government funding and resources, Fucunbao helps subsidize insurance and medical expenses, addressing the financial burdens that often result from healthcare challenges in these areas.
Medilink Therapeutics
Series A in 2021
MediLink Therapeutics is a biotechnology company based in Suzhou, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company aims to address significant unmet medical needs in China by creating innovative therapeutics that target cancer while minimizing damage to healthy cells. MediLink Therapeutics is committed to enhancing patient outcomes through its research and development efforts, which include conducting multicenter clinical trials and engaging in cross-border collaborations to generate global value. By focusing on ADCs, the company strives to improve the efficacy of cancer treatments while ensuring patient safety during therapy.
Hangzhou Weier
Series B in 2021
Hangzhou Weier develops AI and NLP-based customer service robots. They provide solutions for CRM, smart documentary, smart work order, shopping guide magic disk, sky eye guardian, and cloud watch. They also provide smart delivery, customer acquisition, label, SMOT moment, customer service center, and supply chain.
XSKY Data Technology
Series E in 2021
XSKY Beijing Data Technology Corporation Limited is a Chinese company that specializes in software-defined infrastructure products and services aimed at delivering innovative storage solutions for enterprises. By integrating internet carrier operations and mainstream open-source technologies, XSKY offers scalable storage solutions that facilitate cost-effective horizontal expansion for data centers. The company is a significant contributor to the open-source storage system Ceph, ranking among the top three globally and leading in China for source code contributions. Additionally, XSKY is the exclusive storage solution partner of Red Hat China and collaborates with major IT companies like Intel, Samsung, Dell, and Mellanox. Its products are utilized by early adopters in various sectors, including financial services, transportation, telecommunications, and energy, highlighting its commitment to enhancing data management and infrastructure innovation.
Liangyihui
Series C in 2021
Suzhou Liangyihui Network Technology Co., Ltd. operates an authoritative online education and information platform focused on oncology. Based in Shanghai, China, the company collaborates with numerous reputable hospitals and institutions, both domestically and internationally, to address the information asymmetry in the cancer field. Liangyihui provides a comprehensive range of educational materials related to tumor treatment, including medical cases, conference information, online courses, and research reports. This platform serves as a valuable resource for oncologists and aims to enhance public understanding of cancer, promoting scientific knowledge and supporting efforts to prevent and combat the disease.
Miaoshou Doctor
Series E in 2021
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.
Erwan Technology
Series D in 2021
Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.
Erwan Technology
Series E in 2021
Erwan Technology is an online education provider based in Dalian Shi, Liaoning, China, specializing in financial investment education for Chinese middle-class families. Founded in 2016, the company offers a variety of paid educational modules, including live broadcasts, boutique investment courses, and hands-on workshops, aimed at equipping users with essential financial skills. With a focus on making financial education accessible, Erwan Technology has reached over 10 million middle-class students across 34 provincial administrative regions, establishing itself as the largest online investment education platform by user base and ranking among the top three platforms by revenue. The company’s mission is to enhance financial literacy by covering topics such as investment strategies, risk management, and wealth management.
WeRide
Series B in 2021
WeRide is a leading, commercial-stage global company that develops Level 4 autonomous driving technologies. WeRide aims to develop safe and reliable driverless solutions to make mobility and transportation safer, more affordable and accessible. WeRide is conducting autonomous driving R&D, tests and operations in over 25 cities around the world. As the pioneer leader in autonomous technologies and services, WeRide has stepped up to the commercial stage in operations. WeRide offers an all-rounded product mix of Robotaxi, Robobus, Robovan, Robosweeper and ADAS, providing smart services in online ride-hailing, on-demand transport, urban logistics, sanitation services and acting as a solution provider. Established in 2017, WeRide is headquartered in Guangzhou, China, and has expanded its R&D and operation centers to Beijing, Shanghai, Shenzhen, Zhengzhou, Nanjing, Wuhan, and Anqing, as well as San Francisco in the US. WeRide has formed strategic partnerships with leading global OEMs and Tier 1 supplier including Renault-Nissan-Mitsubishi Alliance, Yutong Group, GAC Group, Bosch, etc.
Abbisko Therapeutics
Series D in 2021
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Kira Pharmaceuticals
Series B in 2021
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.
Cornerstone Robotics
Series A in 2021
Cornerstone Robotics operates to improve the accessibility of high-end medical services in China.
Insight Lifetech
Series C in 2020
Insight Lifetech is a medical technology company focused on creating innovative solutions for the diagnosis and treatment of cardiovascular diseases. It has developed a synergistic platform that integrates research and development, manufacturing, and commercialization, which enhances collaboration, accelerates product development, and promotes cost efficiency. The company is notable for creating the first and only domestic fractional flow reserve (FFR) system in China that has received approval from the National Medical Products Administration (NMPA). By manufacturing high-quality medical devices that feature reliable precision diagnostics and therapeutic capabilities, Insight Lifetech aims to empower physicians to improve patient outcomes and save lives.
Microtech Medical
Series D in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
dMed
Series C in 2020
dMed is a full-service Clinical Contract Research Organization that provides industry solutions to pharma and medical device companies. Its business covers consulting, regulatory affairs & strategy, early clinical development, clinical science & medical affairs, clinical operations, biostatistics & programming, data management, drug safety & pharmacovigilance, quality assurance, and information solutions. dMed has set up offices in major cities, including Shanghai, Beijing, Wuhan, New York, Washington, San Francisco, and Brussels, and it employs around 600 professionals globally, among them 60% holds master above degree and 25% with more than 10 years working experiences.
Asieris Pharmaceuticals
Series D in 2020
Asieris Pharmaceuticals Co. Ltd. is a Chinese biotechnology company established in 2010, headquartered in Taizhou, China. The company specializes in the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. Asieris is committed to advancing therapeutic solutions that integrate both diagnosis and treatment, catering to the needs of patients in China and globally. Through its innovative approach, the company seeks to contribute significantly to the fields of oncology and infectious disease management.
InventisBio
Series D in 2020
InventisBio Inc. is a biotechnology company focused on discovering and developing innovative therapeutics for cancer and metabolic diseases. Founded in 2013 and based in Pudong, China, the company specializes in targeted therapies, particularly for lung cancer, breast cancer, and gout. Its product pipeline includes small molecule drug candidates, such as D-0316, a third-generation EGFR-T790M tyrosine kinase inhibitor. InventisBio is also engaged in developing novel immuno-oncology therapies that can be used in conjunction with existing treatments like PD-1 antibodies for various cancer types. The company was co-founded by Dr. Yaolin Wang and other scientists with extensive experience in drug discovery at leading pharmaceutical firms, focusing on significant health challenges such as tumors and metabolic disorders.
Shukun
Series B in 2020
Shukun Technology is a Chinese healthcare company, established in 2017 and based in Beijing, that focuses on developing diagnostic systems utilizing machine learning and artificial intelligence. The company specializes in assisting medical professionals with the diagnosis of cardiovascular diseases and tumors by employing deep learning algorithms to analyze medical images. This technology enables the automatic identification of lesions and the generation of diagnostic reports, thereby enhancing the efficiency of the diagnostic process for doctors and improving the quality of care provided in primary hospitals.
Antengene
Series C in 2020
Antengene Corporation is a biopharmaceutical company based in Shanghai, China, founded in 2016, that specializes in the development of innovative therapies for cancer treatment. The company's portfolio includes ATG-010 (selinexor), targeting hematologic malignancies such as multiple myeloma, and ATG-008 (onatasertib), an mTOR kinase inhibitor aimed at treating advanced solid tumors and hematological malignancies. Antengene's pipeline features several investigational products, including ATG-016 (eltanexor), ATG-527 (verdinexor), and ATG-019, along with pre-clinical candidates like ATG-101, a bi-specific antibody, and ATG-012, a KRAS G12C inhibitor. The company is committed to addressing unmet medical needs in Asia through its focus on the discovery, development, and commercialization of first-in-class therapeutics for various types of cancer.
Tungee
Series B in 2020
Tungee, established in 2016, is a provider of intelligent sales solutions for business-to-business enterprises. By utilizing big data and artificial intelligence technologies, including natural language processing and machine learning, Tungee offers a comprehensive platform that facilitates lead mining, business opportunity engagement, customer relationship management, and order analysis. This platform is designed to help enterprises efficiently identify, contact, and manage customers, thereby reducing customer acquisition costs and enhancing overall sales performance. Tungee has positioned itself as a leader in the Chinese intelligent sales sector, serving over 3,000 enterprise clients, including notable companies such as Alibaba and China Mobile. Through its innovative approach, Tungee addresses the challenges faced by businesses in sales forecasting and customer management.
New Horizon Health
Series E in 2020
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
52toys
Secondary Market in 2020
Animation and Intellectual Property Operator based in Beijing.
XSKY Data Technology
Series D in 2020
XSKY Beijing Data Technology Corporation Limited is a Chinese company that specializes in software-defined infrastructure products and services aimed at delivering innovative storage solutions for enterprises. By integrating internet carrier operations and mainstream open-source technologies, XSKY offers scalable storage solutions that facilitate cost-effective horizontal expansion for data centers. The company is a significant contributor to the open-source storage system Ceph, ranking among the top three globally and leading in China for source code contributions. Additionally, XSKY is the exclusive storage solution partner of Red Hat China and collaborates with major IT companies like Intel, Samsung, Dell, and Mellanox. Its products are utilized by early adopters in various sectors, including financial services, transportation, telecommunications, and energy, highlighting its commitment to enhancing data management and infrastructure innovation.
Shukun
Series B in 2020
Shukun Technology is a Chinese healthcare company, established in 2017 and based in Beijing, that focuses on developing diagnostic systems utilizing machine learning and artificial intelligence. The company specializes in assisting medical professionals with the diagnosis of cardiovascular diseases and tumors by employing deep learning algorithms to analyze medical images. This technology enables the automatic identification of lesions and the generation of diagnostic reports, thereby enhancing the efficiency of the diagnostic process for doctors and improving the quality of care provided in primary hospitals.
Miaoshou Doctor
Series D in 2020
Miaoshou Doctor is a healthcare service platform for building an online communication service platform between patients and doctors. It helps healthcare professionals and patients to manage post-diagnosis outcomes and allows doctors to actively follow up with their patient's health through additional counseling and prescriptions. Tao He and Daoliang Han founded the company in 2015 and is based in Beijing, Beijing.
OriginCell
Series A in 2020
OriginCell is a biomedical equipment enterprise that develops tumor immuno-therapy solutions. It develops tumor therapies and cellular drugs through the use of the 10-phage display library, humanized antibody technology platform, and antibody discovery platform that enable their medical facilities to apply in cancer treatments. OriginCell was founded in 2014 and is headquartered in Shanghai, China.
Microtech Medical
Venture Round in 2020
MicroTech Medical, established in January 2011 in Hangzhou Future Technical City, focuses on the research, development, manufacturing, and commercialization of diabetes management devices. The company aims to innovate and produce high-tech and affordable medical devices for diabetes care, including both treatment and monitoring solutions. With a significant portion of its revenue generated in China, MicroTech Medical is dedicated to enhancing diabetes management both domestically and globally. The company has received investment from Eli Lilly and Company, which underscores its commitment to advancing diabetes care technology.
New Horizon Health
Series D in 2020
New Horizon Health develops advanced technology for the detection and screening of gastrointestinal cancers, with a primary focus on colorectal cancer. The company offers innovative products that utilize fecal gene analysis, allowing individuals to perform home tests that can identify signs of colon cancer and detect precancerous lesions more effectively than traditional blood tests. Established in 2015 and headquartered in Hangzhou, China, with an office in Beijing, New Horizon Health aims to enhance cancer screening accessibility through biotechnology. The company is dedicated to reducing cancer morbidity and mortality rates by promoting early detection and preventive measures, ensuring that high-quality health services reach households across the region. Its product lineup includes ColoClear and Pupu Tube, which are key revenue generators within its pipeline of screening solutions.
Abbisko Therapeutics
Series C in 2020
Abbisko Therapeutics Co. Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on discovering, developing, and manufacturing innovative immuno-oncology therapies. Founded in 2016 by a team with extensive experience in drug research and management, the company specializes in small molecule therapies for various conditions, including cancer, metabolic diseases, liver diseases, viral infections, and central nervous system disorders. Abbisko's notable products include ABSK011 and ABSK021, which are designed to treat hepatocellular carcinoma, as well as CSF1R, aimed at addressing solid tumors. The company is dedicated to advancing its pipeline of therapeutics to improve patient outcomes in oncology and beyond.
Berry Oncology
Series A in 2020
Berry Oncology develops medical technology intended to improve cancer prevention and tumor diagnosis. It offers genetic diagnosis solutions from early diagnosis to mid-late monitoring that can solve clinical problems in the direction of several malignant tumors, providing patients with a higher quality of life and reduced risk of cancer. The company's mission is early diagnosis and early treatment of all tumors, all patients receive precise treatment. Along with its vision to become a global icon in the field of early screening and early diagnosis of tumors and a leader in China's tumor gene testing market.
Kira Pharmaceuticals
Series B in 2020
Kira Pharmaceuticals is a biotechnology company founded in 2017 and based in Suzhou, China. It specializes in developing complement-targeted therapies aimed at treating immune-mediated diseases. The company focuses on pioneering drug discovery related to the complement system, with the goal of providing transformative therapies for individuals suffering from complement-mediated conditions.
Jacobio Pharmaceuticals
Series C in 2020
Jacobio Pharmaceuticals, established in 2015 in Beijing, is a clinical-stage biotech company focused on developing innovative drugs to address unmet medical needs in China and internationally. The company aims to become a global leader in providing transformative therapies for serious conditions, including cancer, autoimmune, and infectious diseases. Founded by experienced executives from prominent pharmaceutical companies, Jacobio has quickly built a robust drug research and development team exceeding 100 employees, equipped with comprehensive capabilities covering target discovery, medicinal chemistry, pharmacology, and clinical development. The company boasts a promising pipeline of 8 to 10 drug candidates, with JAB-3068 being the most advanced. This program targets a novel potential for both immunotherapy and targeted therapy and is currently undergoing Phase I clinical trials in the United States, with approvals secured for trials in China.
DST Car
Series C in 2020
Dishangtie is a Shenzhen-based new energy vehicle rental service platform targeting the transportation and logistics industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.